Sunday, January 29, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Biology

New tool mines whole-exome sequencing data to match cancer with best drug

March 29, 2016
in Biology
0
Share on FacebookShare on Twitter
IMAGE

A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.

"Whole exome sequencing is becoming more available to patients and this tool will help them distill the sequencing data to candidate genes and link them with therapies," says Aik Choon Tan, PhD, investigator at the CU Cancer Center, associate professor of Bioinformatics at the CU School of Medicine, and the paper's senior author.

The tool, called Integrating Molecular Profiles with Actionable Therapeutics, or IMPACT, starts with the data generated by whole-exome sequencing – a string of A, T, C and G hundreds of millions of letters long. IMPACT then maps this string onto the human genome to partition the raw data into segments that correspond to the body's approximately 20,000 genes. The tool then compares the code of these genes to "normal" gene patterns to discover which genes differ in ways that could guide the development of cancer. (In a second step, IMPACT also counts the number of gene repeats, which when adjusted higher or lower can also drive the growth of cancer.)

"Now we have a list of candidate genes," Tan says. "The next step is to link candidate genes with therapeutics."

IMPACT does this by mining publicly available data including that of the NCI-MATCH clinical trial and the database at MyCancerGenome.org to discover which FDA-approved therapies target these candidate genes.

The Tan lab tested the tool by inputting whole-exome sequencing data for patients known to have EGFR-mutated non-small cell lung cancer from The Cancer Genome Atlas. Sure enough, IMPACT successfully identified the gene EGFR as a driving mutation and recommended FDA-approved EGFR inhibitors.

In collaboration with the laboratory of CU Cancer Center investigator William A. Robinson, MD, PhD, Tan and colleagues then used the tool to retrospectively analyze a series of exome-sequences from patients diagnosed with melanoma, validating the tool's ability to discover a patient's activating mutation and pair it with useful treatment.

"For example, a patient was found to have a BRAF mutation and was put on a clinical trial of the drug vemurafenib, which targets BRAF alterations," Tan says.

The drug controlled the patient's tumor. However, two years later the tumor relapsed. At this point, the group resequenced the tumor and found that in addition to BRAF mutation, the patient had developed NRAS mutation.

"Taking tumor samples over time, we could see the cancer cell figuring out how to become resistant," Tan says.

However, drugs also exist to disrupt cells that depend on NRAS mutation. The combination of dabrafenib (for BRAF) and trametinib (for NRAS) controlled the patient's melanoma for another two years. When the cancer relapsed, it was again resequenced and evaluated using IMPACT. Analysis showed loss of the gene CDKN2a, a known tumor suppressor gene that keeps in check cells that have learned to speed through the process of replication. Currently there are no inhibitors of the CDK family of genes approved by the FDA to treat melanoma. However, the drug palbocicilib recently earned FDA approval to treat a subset of breast cancers.

"We are trying to see if we can treat this melanoma with a CDK inhibitor. Will this drug overcome the cancer's resistance to the previous combination?" Tan says.

The IMPACT tool works in four steps: 1) identify possible cancer-causing mutations; 2) identify possible cancer-causing gene copy number alterations; 3) match cancer's genetic causes with the most likely therapeutic controls; 4) evaluate the ongoing evolution of cancer to continue matching controls with emerging causes.

"We hope that IMPACT proves to be an important tool in empowering the shift toward precision medicine," Tan says.

###

Media Contact

Garth Sundem
[email protected]
@CUAnschutz

http://www.ucdenver.edu

Share25Tweet16Share4ShareSendShare
  • Logo

    New study shows snacking on mixed tree nuts may impact cardiovascular risk factors and increase serotonin

    103 shares
    Share 41 Tweet 26
  • Null results research now published by major behavioral medicine journal

    533 shares
    Share 213 Tweet 133
  • New study debunks the assumption that menstrual cycles disqualify women from exercise research

    65 shares
    Share 26 Tweet 16
  • Constructor University professor publishes outstanding psychological research paper

    76 shares
    Share 30 Tweet 19
  • Ignoring Native American data perpetuates misleading white ‘deaths of despair’ narrative, study finds

    67 shares
    Share 27 Tweet 17
  • The next generation of global health innovators: Michelson Prize winners announced

    66 shares
    Share 26 Tweet 17
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

New study shows snacking on mixed tree nuts may impact cardiovascular risk factors and increase serotonin

Hydrogen peroxide from tea and coffee residue: New pathway to sustainability

Null results research now published by major behavioral medicine journal

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 205 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In